Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurologix has reported net loss of $2.08m for the first quarter ended 31 March 2011, or $0.10 loss per diluted share, as compared to $3.5m or $0.15 loss per diluted share for the same period in 2010.
Subscribe to our email newsletter
Neurologix is a clinical-stage biotechnology company engaged in discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system.
The company’s loss from operations was $2.06m, compared to $3.14m for the same period last year.
Neurologix president and CEO Clark Johnson said they are continuing on the path to develop NLX-P101, their Parkinson’s disease gene transfer therapy, as a much needed therapy for patients with Parkinson’s disease and plan to submit a Phase 3 protocol to the FDA later this year.